Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co.

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target reduced by investment analysts at JPMorgan Chase & Co. from $120.00 to $74.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 243.95% from the company’s current price.

A number of other equities analysts also recently commented on RARE. Bank of America decreased their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. HC Wainwright dropped their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Guggenheim reduced their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Finally, Wedbush reaffirmed a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Sixteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.76.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.70 during trading hours on Thursday, hitting $21.52. 750,029 shares of the company’s stock traded hands, compared to its average volume of 2,463,697. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -3.69 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $42.37. The company has a fifty day simple moving average of $23.08 and a 200-day simple moving average of $28.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business’s quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, EVP Eric Crombez sold 7,029 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares in the company, valued at approximately $1,739,662.80. The trade was a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 54,404 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares in the company, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 104,958 shares of company stock worth $2,394,858. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently modified their holdings of RARE. Covestor Ltd grew its stake in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the last quarter. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Xponance Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 406 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 434 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Ultragenyx Pharmaceutical by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 441 shares during the period. Institutional investors own 97.67% of the company’s stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data showed improved control of ammonia levels in patients with a rare inherited disorder — a clinically meaningful result that supports the program’s value and potential commercial upside. Read More.
• Neutral Sentiment: Management gave investor presentations at the Leerink Global Healthcare and Barclays Global Healthcare conferences this week (transcripts available). These presentations recap pipeline strategy and commercial plans but did not contain new regulatory or financial milestones that would immediately change valuation. Read More. Read More.
• Negative Sentiment: Multiple law firms and shareholder‑alert services issued class‑action notices and lead‑plaintiff reminders tied to a securities lawsuit alleging investor harm (class period Aug 3, 2023–Dec 26, 2025). Firms named in notices include Pomerantz, Schall, DJS, Rosen, Faruqi & Faruqi, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and others — one firm specifically flagged potential control‑person claims naming the CEO and CMO. The wave of filings/solicitations raises litigation overhang and potential settlement exposure, which is likely weighing on the stock. Read More.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.